SCHEMBL30431649

SCHEMBL30431649

O=C(CCl)NCc1nn(-c2ccc(OC(F)(F)F)cc2)c2ccccc12

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TEAD1 P28347 3/20 0.66
▸ TEAD4 Q15561 3/20 0.66
▸ TEAD2 Q15562 3/20 0.66
▸ TEAD3 Q99594 3/20 0.66
▸ PTGER4 P35408 2/20 0.47
▸ ABCB1 P08183 1/20 0.45
▸ SCN9A Q15858 3/20 0.44
▸ RARG P13631 1/20 0.41
▸ RORC P51449 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ CACNA1G O43497 1/20 0.40
▸ CACNA1H O95180 1/20 0.40
▸ CACNA1I Q9P0X4 1/20 0.40
▸ LTA4H P09960 1/20 0.40
▸ EPHX2 P34913 1/20 0.40
▸ TRPV1 Q8NER1 1/20 0.39
▸ CA12 O43570 1/20 0.39
▸ CA1 P00915 1/20 0.39
▸ CA2 P00918 1/20 0.39
▸ CA7 P43166 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25237436 1.00 TEAD1 (0.66) TEAD1TEAD4TEAD2TEAD3PTGER4
SCHEMBL25750434 0.93 TEAD1 (0.62) TEAD1TEAD4TEAD2TEAD3PTGER4
SCHEMBL30469096 0.90 TEAD1 (0.61) TEAD1TEAD4TEAD2TEAD3PTGER4
SCHEMBL25232419 0.90 TEAD1 (0.61) TEAD1TEAD4TEAD2TEAD3PTGER4
SCHEMBL25237292 0.88 TEAD1 (0.61) TEAD1TEAD4TEAD2TEAD3PTGER4
SCHEMBL25749012 0.87 TEAD1 (0.63) TEAD1TEAD4TEAD2TEAD3PTGER4
SCHEMBL25247529 0.84 TEAD1 (0.60) TEAD1TEAD4TEAD2TEAD3PTGER4
SCHEMBL30431703 0.84 TEAD1 (0.57) TEAD1TEAD4TEAD2TEAD3PTGER4
SCHEMBL25238957 0.84 TEAD1 (0.57) TEAD1TEAD4TEAD2TEAD3PTGER4
SCHEMBL25747721 0.84 RARG (0.48) TEAD1TEAD4TEAD2TEAD3SCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12110276-B2 Pyrazolo compounds and methods of use thereof GENENTECH, INC. (US) 2024-10-08 — — US claimed
US-20230202984-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE GENENTECH, INC. (US) 2023-06-29 — — US claimed
US-20250074881-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE GENENTECH, INC. (US) 2025-03-06 — — US disclosed
US-12110276-B2 Pyrazolo compounds and methods of use thereof GENENTECH, INC. (US) 2024-10-08 — — US disclosed
CN-118302411-A Therapeutic indazole compounds and methods of use thereof for the treatment of cancer 基因泰克公司 2024-07-05 — — CN disclosed
US-20230202984-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE GENENTECH, INC. (US) 2023-06-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250074881-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE VHL, TP53, MCL1 TEAD1 282/4885TEAD4 162/4885TEAD2 129/4885
US-20230202984-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE VHL, TP53, MCL1 TEAD1 282/4885TEAD4 162/4885TEAD2 129/4885
US-12110276-B2 Pyrazolo compounds and methods of use thereof THPO, KLK3, TP53 TEAD1 390/4885TEAD4 240/4885TEAD2 200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback